How are energy investors positioned?
LONDON - British American Tobacco (NYSE:BTI) PLC (BAT (LON:BATS)) has announced the appointment of Uta Kemmerich-Keil as an independent Non-Executive Director, effective from February 17, 2025. Kemmerich-Keil will also serve on the company’s Audit and Nominations Committees.
Kemmerich-Keil’s previous roles include CEO of Personal Healthcare International at Procter & Gamble (NYSE:PG) from 2018 to 2020, and various leadership positions at Merck (NSE:PROR) Group, including CEO of the Consumer Health Division. She is currently a member of the Supervisory Board and Chair of the Audit Committee at Beiersdorf (ETR:BEIG).
BAT’s Chair of the Board, Luc Jobin, expressed confidence in Kemmerich-Keil’s background in regulated industries and her experience in consumer products, digital technology, and strategic transformation, stating these skills will be valuable to BAT’s goal of creating a smokeless future.
Concurrently, BAT announced that Murray S. Kessler will resign from the Board on February 17, 2025, to take on the role of Chief Executive Officer at Wellington International LLC. Jobin thanked Kessler for his contributions and insights during his tenure.
In related news, Karen Guerra, a Non-Executive Director at BAT, will join the Remuneration Committee and leave the Audit Committee as of February 10, 2025. The reshuffling follows a review of the Board Committees’ membership, which will see Darrell Thomas continue as Chair of the Audit Committee and Kandy Anand as Chair of the Remuneration Committee.
The changes to the Board and its committees come as part of BAT’s ongoing corporate governance and strategic planning. These appointments and departures are based on a press release statement from British American Tobacco.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.